Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

B. Benson, Al; I. D’Angelica, Michael; E. Abbott, Daniel; A. Anaya, Daniel; A. Anders, Robert; Are, Chandrakanth; Bachini, Melinda; J. Borad, Mitesh; B. Brown, Daniel; M. Burgoyne, Adam; Chahal, Prabhleen; T. Chang, Daniel; M. Cloyd, Jordan; M. Covey, Anne; S. Glazer, Evan; Goyal, Lipika; G. Hawkins, William; Iyer, Renuka; Jacob, Rojymon; Kate Kelley, Robin; D. Kim, Robin; H. Levine, Matthew; Palta, Manisha; O. Park, James; S. Raman, Steven; S. Reddy, Sanjay; Sahai, Vaibhav; E. Schefter, Tracey; Singh, Gagandeep; Stein, Stacey; Vauthey, Jean‐Nicolas; P. Venook, Alan; C. Yopp, Adam; R. McMillian, Nicole; Hochstetler, Cindy; Darlow, Susan

doi:10.6004/jnccn.2021.0022

Public

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Published in Journal of the National Comprehensive Cancer Network • May 1, 2021

Authors:

Al B. Benson

Michael I. D’Angelica

Daniel E. Abbott

Abstract

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used ...

Subject

Medicine

Sorafenib

Hepatocellular carcinoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!